A long-run study looking into leading Firebrick Pharma (ASX:FRE) product Nasodine has suggested the nasal spray can be an effective treatment for the common cold following a dive into the company’s Phase III trials.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The study, published in the open-access journal Frontiers in Medicine, suggested Nasodine reduced overall cold severity by 40% compared to saline nasal spray when treatment was started in the first 24 hours.
The findings from the Nasodine study concluded: “In the current study, Nasodine 0.5% PVP-I nasal spray demonstrated a consistently positive benefit in reducing overall cold severity outcomes compared to saline nasal spray.”
Clinical pharmacologist Dr Tom Polasek, who led the study at Monash University, also declared that “[Nasodine] was safe and well-tolerated” in several tests.
“Clinically and scientifically, this was an important trial, being the first pivotal study to demonstrate that a topical agent like povidone-iodine can be an effective treatment for upper respiratory infection,” Dr Polasek further explained.
Worth noting — the Nasodine trials today under the microscope were run in 2019.
How long the study took hasn’t stopped celebrations, though, with chairman Dr Peter Molloy saying it leads to “a much richer and more accurate understanding of the results.”
Firebrick Pharma is also planning to use the study as much as possible, with the company already planning ways to market the findings. “This paper will become an important addition to the marketing of Nasodine to healthcare professionals in all markets where the product is currently sold,” Dr Molloy said.
How that Nasodine marketing will roll out has not been confirmed at time of writing.
FRE is selling at 6.7cps as ASX trading opens on Tuesday.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
